公开(公告)号：US11897847B2

公开(公告)日：2024-02-13

申请号：US17058709

申请日：2019-05-29

Applicant: BASF SE

Inventor： Martin Viertelhaus ,  Rolf Hellmann ,  Tobias Seiser ,  Cyrill Zagar ,  Gregory Armel ,  Ulrich Steinbrenner

IPC: C07D239/54 ,  A01N43/54

CPC classification number: C07D239/54 ,  A01N43/54 ,  C07B2200/13

Abstract: The present invention relates to one crystalline form A of ethyl 2-[2-[2-chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy]phenoxy]acetate, a process for the production of this crystalline form, formulations for plant protection and herbicidal compositions comprising such form A.

公开(公告)号：US11292784B2

公开(公告)日：2022-04-05

申请号：US16764432

申请日：2018-11-08

Applicant: BASF SE

Inventor： Martin Viertelhaus ,  Rolf Hellmann ,  Dennis Koulelis ,  Tobias Seiser

IPC: C07D401/14

Abstract: The present invention relates to crystalline forms of ethyl 2-[[3-[[3-chloro-5-fluoro-6-[3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]-2-pyridyl]oxy]-2-pyridyl]oxy]acetate, herein after also referred to as “compound of formula (I)”. The invention also relates to a process for the production of these crystalline forms, formulations for plant protection and herbicidal compositions which contain one of these crystalline forms.

公开(公告)号：US09221789B2

公开(公告)日：2015-12-29

申请号：US14406264

申请日：2013-06-18

Applicant: BASF SE

Inventor： Tiziana Chiodo ,  Rolf Hellmann ,  Marcus Vossen ,  Beate Salvador ,  Andreas Hafner ,  Tobias Hintermann

IPC: A61K31/506 ,  C07D401/04 ,  C07C55/10 ,  C07C57/15 ,  C07C63/06

CPC classification number: C07D401/04 ,  C07B2200/13 ,  C07C55/10 ,  C07C57/15 ,  C07C63/06

Abstract: Novel solid forms of imatinib mesilate comprising as active ingredient 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]-benzamide methanesulfonic acid salt and as co-crystal former benzoic acid, fumaric acid or succinic acid are described. The said multi-component crystalline forms possess improved physical and biological properties with respect to the crystalline forms of the active pharmaceutical ingredient previously known.

Abstract translation: 包含作为活性成分的4 - [（4-甲基-1-哌嗪基）甲基] -N- [4-甲基-3 - [[4-（3-吡啶基）-2-嘧啶基]氨基] - 苯基] - 苯甲酰胺甲磺酸盐和共结晶前体苯甲酸，富马酸或琥珀酸。 所述多组分结晶形式相对于先前已知的活性药物成分的结晶形式具有改善的物理和生物学性质。

公开(公告)号：US20150126520A1

公开(公告)日：2015-05-07

申请号：US14406264

申请日：2013-06-18

Applicant: BASF SE

Inventor： Tiziana Chiodo ,  Rolf Hellmann ,  Marcus Vossen ,  Beate Salvador ,  Andreas Hafner ,  Tobias Hintermann

IPC: C07D401/04 ,  C07C55/10 ,  C07C57/15 ,  C07C63/06

CPC classification number: C07D401/04 ,  C07B2200/13 ,  C07C55/10 ,  C07C57/15 ,  C07C63/06

Abstract: Novel solid forms of imatinib mesilate comprising as active ingredient 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]-benzamide methanesulfonic acid salt and as co-crystal former benzoic acid, fumaric acid or succinic acid are described. The said multi-component crystalline forms possess improved physical and biological properties with respect to the crystalline forms of the active pharmaceutical ingredient previously known.

Abstract translation: 包含作为活性成分的4 - [（4-甲基-1-哌嗪基）甲基] -N- [4-甲基-3 - [[4-（3-吡啶基）-2-嘧啶基]氨基] - 苯基] - 苯甲酰胺甲磺酸盐和共结晶前体苯甲酸，富马酸或琥珀酸。 所述多组分结晶形式相对于先前已知的活性药物成分的结晶形式具有改善的物理和生物学性质。

公开(公告)号：US20210206729A1

公开(公告)日：2021-07-08

申请号：US17058709

申请日：2019-05-29

Applicant: BASF SE

Inventor： Martin Viertelhaus ,  Rolf Hellmann ,  Tobias Seiser ,  Cyrill Zagar ,  Gregory Armel ,  Ulrich Steinbrenner

IPC: C07D239/54 ,  A01N43/54

Abstract: The present invention relates to one crystalline form A of ethyl 2-[2-[2-chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy]phenoxy]acetate, a process for the production of this crystalline form, formulations for plant protection and herbicidal compositions comprising such form A.

公开(公告)号：US10105355B2

公开(公告)日：2018-10-23

申请号：US15501908

申请日：2015-08-03

Applicant: BASF SE

Inventor： Martin Viertelhaus ,  Tiziana Chiodo ,  Beate Salvador ,  Marcus Vossen ,  Andreas Hafner ,  Tobias Hintermann ,  Walter Weishaar ,  Rolf Hellmann

IPC: C07D213/40 ,  A61K31/4402

Abstract: The present invention primarily relates to multi-component crystals comprising a compound of formula 1 and a second compound selected from the group consisting of co-crystal formers and solvents. The invention is further related to pharmaceutical compositions comprising such multi-component crystals. Furthermore, the invention relates to processes for preparing said multi-component crystals. The invention also relates to several aspects of using said multi-component crystals or pharmaceutical compositions to treat a disease.